Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Disease
- Therapeutic
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 295927
License Grant
Licensor granted Licensee worldwide exclusive licenses, with the right to grant sublicenses, to our patent rights and know-how with respect to such compounds and products. Licensee is responsible for pursuing worldwide clinical development of compounds from the research program and has the exclusive right to develop and commercialize compounds from the collaboration to further develop and commercialize compounds identified under our Foundation sponsored research program with the Foundation and to research other small molecule compounds with potential for therapeutic use in patients with Foundation.
License Property
Licensor developed several high-throughput drug discovery technology platforms that enable us to identify small molecule modifiers of pre-mRNA splicing. These technologies rely on sensitive quantification of pre-mRNA isoforms directly in human cells or tissue samples. Using this technology, we have successfully identified orally bioavailable small molecules that correct splicing of SMN2 mRNA. One of these molecules, risdiplam, is a potential treatment for the genetic disorder SMA.
Field of Use
The small molecule compounds with the potential for therapeutic use in patients with Spinal Muscular Atrophy (SMA).
Spinal muscular atrophy is a genetic disorder characterized by weakness and wasting (atrophy?) in muscles used for movement (skeletal muscles). It is caused by a loss of specialized nerve cells, called motor neurons that control muscle movement. The weakness tends to be more severe in the muscles that are close to the center of the body (proximal) compared to muscles away from the body's center (distal). The muscle weakness usually worsens with age.
IPSCIO Record ID: 190271
License Grant
Licensor granted an exclusive worldwide option and collaboration agreement under which both companies will develop and commercialize the antisense investigational drug candidate, SPINRAZA, for the treatment of spinal muscular atrophy or SMA. Licensee exercised the option to develop and commercialize SPINRAZA.
License Property
SPINRAZA is an antisense oligonucleotide. Antisense drugs are small snippets of synthetic genetic material that bind to ribonucleic acid (RNA), so they can be used to fix splicing errors in genes such as SMN2.
SPINRAZA is approved by the U.S. Food and Drug Administration for the treatment of SMA in pediatric and adult patients in the U.S.
Spinal muscular atrophy (SMA) is a genetic disease affecting the part of the nervous system that controls voluntary muscle movement.
Field of Use
SPINRAZA® (nusinersen) is a prescription medicine used to treat spinal muscular atrophy (SMA) in pediatric and adult patients.
Licensee is a biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological and neurodegenerative diseases.
IPSCIO Record ID: 316237
License Grant
Under the terms of the Asset Purchase Agreement with Party A, the Danish Licensee became party to a royalty agreement with the Trust for worldwide net sales of Arimoclomol for the treatment of Amyotrophic Lateral Sclerosis (ALS). Pursuant to this Asset Agreement, Party A sold and transferred certain preclinical and clinical data, patents and other intellectual property rights, and other assets, including contractual rights and obligations relating to a portfolio of chemical compounds, including arimoclomol, to Licensee.
License Property
Arimoclomol is an orally- or naso/gastrically-administered small molecule that crosses the blood-brain barrier and is designed to selectively amplify the natural role of endogenous Heat Shock Proteins (HSPs), which protect against cellular toxicity caused by protein misfolding, aggregation and lysosomal dysfunction.
The Trust is the charitable remainder beneficiary that generates a potential income stream from donors, or other beneficiaries, to benefit the research of ALS.
Amyotrophic lateral sclerosis or ALS, is a progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing loss of muscle control. ALS is often called Lou Gehrig's disease.
Field of Use
The Field of Use is for the treatment or prevention of Amyotrophic Lateral Sclerosis (ALS). ALS, commonly referred to as Lou Gehrig’s disease, is a rapidly progressing neurological disease with the onset of symptoms typically occurring between 40 to 70 years of age, with patient mortality occurring in most patients within three to five years of disease onset. ALS attacks neurons responsible for controlling voluntary muscles, resulting in muscle weakness in limbs, and impacts speaking, chewing, swallowing and breathing, leading to progressive disability and eventually death, typically from respiratory failure and aspiration pneumonia.
Licensee is biopharmaceutical company harnessing the amplification of Heat Shock Proteins, or HSPs, in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases that includes Amyotrophic Lateral Sclerosis (ALS), commonly referred to as Lou Gehrig’s disease.
IPSCIO Record ID: 256305
License Grant
The parties wish to expand their collaboration by engaging in joint activities related to the discovery and development of pharmaceutical products that utilize inventions covered by the Licensor Patents, the Isis Splicing Patents and/or the Licensee Splicing Patents.
License Property
One Party owns or controls certain patents related to morpholino chemistry.
The other Party controls certain patents, the Isis Splicing Patents, related to RNA splicing.
Field of Use
The field of use is to treat Muscular Dystrophy (MD) and Beta Thalassemia (BT).
Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass.
Beta thalassemia is a blood disorder that reduces the production of hemoglobin. Hemoglobin is the iron-containing protein in red blood cells that carries oxygen to cells throughout the body.
IPSCIO Record ID: 256513
License Grant
The parties wish to expand their collaboration by engaging in joint activities related to the discovery and development of pharmaceutical products that utilize inventions covered by the Licensee Patents, the Isis Splicing Patents and/or the Licensor Splicing Patents.
License Property
One Party owns or controls certain patents related to morpholino chemistry.
The other Party controls certain patents, the Isis Splicing Patents, related to RNA splicing.
Field of Use
The field of use is to treat Muscular Dystrophy (MD) and Beta Thalassemia (BT).
Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass.
Beta thalassemia is a blood disorder that reduces the production of hemoglobin. Hemoglobin is the iron-containing protein in red blood cells that carries oxygen to cells throughout the body.
IPSCIO Record ID: 26664
License Grant
The Licensor has granted the Licensee an exclusive License for human applications of our GDF portfolio. The Licensee has a significant development program for Myostatin based on this License. Phase II clinical trials for Myostatin as a therapeutic for treatment of Muscular Dystrophy have been completed.
License Property
Myostatin is being evaluated for treatment of other muscle degenerative diseases, including muscle wasting called Cachexia, age related muscle loss or Sarcopenia, Lou Gehrig’s disease or ALS, and metabolic disorders such as Type II Diabetes and obesity.
Field of Use
The rights granted apply to pharmaceutical companies for human health applications.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
